Coping with esophageal cancer approaches worldwide

Cotton, Richard G.H.; Langer, Rupert; Leong, Trevor; Martínek, Jan; Sewram, Vikash; Smithers, B. Mark; Swanson, Paul E.; Qiao, You‐Lin; Udagawa, Harushi; Ueno, Masaki; Wang, Meng; Wang, Wen; White, Russell E.

doi:10.1111/nyas.12522

Cited by 15 publications

(19 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Of the 37 nonrandomized studies, 17 reported on palliative luminal and surgical interventions ( Table 1). Ten of these studies reported on self-expandable metallic stents (SEMS) 6,[20][21][22][23][24][25][26][27][28] ; five on rigid plastic stents, laser treatment or dilation [29][30][31][32][33] ; and two on retrosternal gastric bypass. 34,35 Four studies reported on palliative radiotherapy, 18,20,32,36 six studies on chemotherapy 32,37-41 and three studies on concurrent chemoradiotherapy 32,42,43 (Table 2).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Thirteen studies were case series reporting outcomes following esophagectomy (Table 3). 6,7,19,32,[44][45][46][47][48][49][50][51][52] All nine RCTs were single-center studies conducted in South Africa (Table 4). Three studies compared intubation with plastic stents to other treatments (dilation with bleomycin, 54 retrosternal gastric bypass 53 and SEMS 60 ), and two evaluated intubation combined with either chemotherapy, radiotherapy or chemoradiation as compared to intubation alone.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…In Africa, nearly 90% of patients have advanced disease at the time of presentation. [5][6][7] For patients with localized or locoregional ESCC, chemoradiation with or without surgery offers the best chance for longterm survival. 8 Palliative treatment strategies, however, remain the mainstay of care for most patients presenting with advanced disease.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Optimal management of esophageal cancer in Africa: A systemic review of treatment strategies

Buckle

Mahapatra

Mwachiro

et al. 2020

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Esophageal cancer (EC) is a leading cause of cancer morbidity and mortality in Africa. Despite the high burden of disease, optimal management strategies for EC in resource‐constrained settings have yet to be established. This systematic review evaluates the literature on treatments for EC throughout Africa and compares the efficacy and safety of varying treatment strategies in this context (PROSPERO CRD42017071546). PubMed, Embase and African Index Medicus were searched for studies published on treatment strategies for EC in Africa from 1980 to 2020. Searches were supplemented by examining bibliographies of included studies and relevant conference proceedings. Methodological quality/risk of bias was assessed using the Cochrane Risk‐of‐Bias tool and the Newcastle‐Ottawa Scale. Forty‐six studies were included. Case series constituted the majority of studies: 13 were case series reporting on outcomes of esophagectomies, 17 on palliative luminal or surgical interventions, four on radiotherapy and three on concurrent chemoradiation. Nine randomized controlled trials were identified, of which four prospectively compared different treatment modalities (one investigating radiotherapy vs chemoradiation, three evaluating rigid plastic stents vs other treatments). This review summarizes the research on EC treatments in Africa published over the last four decades and outlines critical gaps in knowledge related to management in this context. Areas in need of further research include (a) evaluation of the safety and efficacy of neoadjuvant therapy in patients with locally advanced disease; (b) strategies to improve long‐term survival in patients treated with definitive chemoradiation; and (c) the comparative effectiveness of modern palliative interventions, focusing on quality of life and survival as outcome measures.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Optimal management of esophageal cancer in Africa: A systemic review of treatment strategies

Buckle

Mahapatra

Mwachiro

et al. 2020

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Esophageal cancer contains two major subtypes, including esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC) [3]. EC has becoming a global serious problem due to threatening life, and ESCC patients with advanced stage tumors commonly harbor poor prognosis [4]. Despite surgery is the traditional treatment for ESCC patients, and developing new therapeutic strategies for ESCC is of great significance.…”

Section: Introductionmentioning

confidence: 99%

LncRNA LOXL1-AS1 promotes esophageal squamous cell carcinoma progression by targeting DESC1

Chu

Jia

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Recently, ample evidence indicated that numerous aberrantly expressed long non-coding RNAs (lncRNAs) participated in the development of multiple malignancies. However, the expression and function of lncRNA LOXL1-AS1 in mediating esophageal squamous cell carcinoma (ESCC) carcinogenesis remains largely elusive. Here we validated that LOXL1-AS1 was significantly upregulated in ESCC tissues compared with the corresponding adjacent non-neoplastic tissues, and LOXL1-AS1 expression was positively correlated with ESCC patients' lymph node metastasis. Besides, LOXL1-AS1 knockdown impaired ESCC cells proliferation, migration and invasion capabilities in vitro . Furthermore, inhibiting LOXL1-AS1 in ESCC cells increased the percentage of cells at the G1 phase, accompanied by reducing in S phase in contrast to scramble control, and silencing of LOXL1-AS1 evoked ESCC cell apoptosis. From high throughput RNA sequencing (RNA-seq) analysis, we identified that differentially expressed in squamous cell carcinoma 1 (DESC1) was a critical downstream target of LOXL1-AS1. Taken together, we demonstrated the function and mechanism of LOXL1-AS1 in contributing ESCC progression for the first time, and indicated LOXL1-AS1 may be a novel therapeutic biomarker of ESCC.

show abstract

“…EC ranks fifth in incidence (21.17 per 100,000), and fourth in mortality (15.58 per 100,000) among all malignant tumors in China (5, 6). Carcinogen exposure (e.g., nitrosamines and their precursors, fungi, trace minerals, and polycyclic hydrocarbons), nutritional deficiency, lifestyles, and genetics contribute to the multistage development of EC through (1) localized injury, (2) inflammation, (3) mutagenesis, and (4) carcinogenesis (7, 8).…”

Section: Introductionmentioning

confidence: 99%

Survival of Esophageal Cancer in China: A Pooled Analysis on Hospital-Based Studies From 2000 to 2018

et al. 2019

View full text Add to dashboard Cite

Background: Esophageal cancer (EC) causes more than 400 thousand deaths per year, and half of them occur in China. There are discrepancies regarding the survival of EC patients between population-based surveillance studies and hospital-based studies. Objectives: We aimed to synthesize the survival data from hospital-based EC studies in the Chinese population from 2000 to 2018 and to compare the survival rates between EC patients with different clinical classifications. Methods: The protocol of this systematic review was registered in PROSPERO (CRD-42019121559). We searched Embase, PubMed, CNKI, and Wanfang databases for studies published between January 1, 2000 and December 31, 2018. We calculated the pooled survival rates and 95% confidence intervals (CIs) by Stata software (V14.0). Results: Our literature search identified 933 studies, of which 331 studies with 79,777 EC patients met the inclusion criteria and were included in meta-analyses. The pooled survival rates were 74.1% (95% CI: 72.6–75.7%) for 1-year survival, 49.0% (95% CI: 44.2–53.8%) for 2-years survival, 46.0% (95% CI: 42.6–49.5%) for 3-years survival, and 40.1% (95% CI: 33.7–46.4%) for 5-years survival. An increased tendency toward EC survival was verified from 2000 to 2018. In addition, discrepancies were observed between EC patients with different clinical classifications (e.g., stages, histologic types, and cancer sites). Conclusions: Our findings showed a higher survival rate in hospital-based studies than population-based surveillance studies. Although this hospital-based study is subject to potential representability and publication bias, it offers insight into the prognosis of patients with EC in China.

show abstract

Coping with esophageal cancer approaches worldwide

Cited by 15 publications

References 58 publications

Optimal management of esophageal cancer in Africa: A systemic review of treatment strategies

Optimal management of esophageal cancer in Africa: A systemic review of treatment strategies

LncRNA LOXL1-AS1 promotes esophageal squamous cell carcinoma progression by targeting DESC1

Survival of Esophageal Cancer in China: A Pooled Analysis on Hospital-Based Studies From 2000 to 2018

Contact Info

Product

Resources

About